Heyholder
‹ Back to the disclosure you were reading

EyeGene,Inc Application to Amend Korean Phase 2/3 Trial Plan for Quadrivalent Meningococcal Conjugate Vaccine EG-MCV4

EyeGene,Inc

AI summary · Not investment advice

The company applied to the MFDS on 2026-11-10 to amend the Korean Phase 2/3 trial plan for its quadrivalent meningococcal vaccine EG-MCV4.

Commentary

AI commentary · Not investment advice

What happened

Aegis-type filing: the company applied to Korea's Ministry of Food and Drug Safety (MFDS) to change the plan for its Phase 2/3 trial of EG-MCV4, a 4-strain meningococcal vaccine. The trial tests immune response and safety in healthy adults. It runs at multiple hospitals, including Eunpyeong St. Mary's Hospital of the Catholic University of Korea.

In the company's terms

The change reflects supplementary requests from the MFDS. Part 1 is Phase 2 with a target of 125 participants. Part 2 is Phase 3 with a target of 998 participants, split into Cohort A with 730 and Cohort B with 268.

What changes for shareholders

The trial period is 30 months from the approval date of the institutional review board (IRB). It can be extended depending on how long participant recruitment takes. The materials do not say when the change will be approved.

Earlier filings of the same type

Filings of the same type
FiledTitleKey figure · Note
26.11.12Nov 12, 2026 · Date MFDS approved the clinical trial plan amendment application

Comments

No comments yet

Comments from shareholders will appear here.